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Abstract
Background: Activating KRAS mutations are important for cancer initiation and progression; and have recently
been shown to cause primary resistance to therapies targeting the epidermal growth factor receptor. Therefore,
strategies are currently in development to overcome treatment resistance due to oncogenic KRAS. The hypoxia-
inducible factors-1a and -2a (HIF-1a and HIF-2a) are activated in cancer due to dysregulated ras signaling.
Methods: To understand the individual and combined roles of HIF-1a and HIF-2a in cancer metabolism and
oncogenic KRAS signaling, we used targeted homologous recombination to disrupt the oncogenic KRAS, HIF-1a,
and HIF-2a gene loci in HCT116 colon cancer cells to generate isogenic HCT116WT KRAS, HCT116HIF-1a-/-, HCT116HIF-
2a-/-, and HCT116HIF-1a-/-HIF-2a-/- cell lines.
Results: Global gene expression analyses of these cell lines reveal that HIF-1a and HIF-2a work together to
modulate cancer metabolism and regulate genes signature overlapping with oncogenic KRAS. Cancer cells with
disruption of both HIF-1a and HIF-2a or oncogenic KRAS showed decreased aerobic respiration and ATP
production, with increased ROS generation.
Conclusion: Our findings suggest novel strategies for treating tumors with oncogenic KRAS mutations.
Introduction
Oncogenic ras mutations (involving HRAS, NRAS, and
KRAS genes) are found in approximately 30% of all
human tumors; with mutations affecting KRAS being
the most prevalent. KRAS mutations are most prevalent
in pancreatic (72-90%), thyroid (55%), colorectal
(32-57%), and lung cancers (15-50%) [1,2,1,2]. Point
mutations at codons 12, 13, or 61 result in stabilization
of KRAS in the GTP-bound conformation, rendering
it constitutively active [3]. Activated ras signaling contri-
butes to oncogenic transformation by providing molecu-
lar signals that promote cell proliferation, obstruct cell
death, inhibit cellular differentiation, and induce angio-
genesis [4]. Underlying these cellular processes, ras
transformed cells also undergo significant metabolic
adaptation [5].
The hypoxia-inducible factors-1a and -2a (HIF-1a
and HIF-2a) are transcription factors that are overex-
pressed in cancer and linked to cancer progression [6,7].
Structurally, HIF-1a and HIF-2a are partially related,
sharing 48% overall amino acid identity and two identi-
cal proline residues in their oxygen-dependent degrada-
tion domains [8,9]. HIF-1a and HIF-2a dimerize with
HIF-1b to form HIF-1 and HIF-2, respectively. HIF-1a
and HIF-2a overexpression are driven by intratumoral
hypoxia, growth factor signaling, and genetic mutations
in oncogenes and tumor suppressor genes [10,11].
Under normoxia, HIF-1a and HIF-2a are ubiquitinated
through an oxygen-dependent interaction with the von
Hippel-Lindau protein (pVHL) and degraded by the 26S
proteasome [12,13]. Under hypoxic conditions, HIF-1a
and HIF-2a proteins accumulate, translocate to the
nucleus, dimerize with HIF-1b, and transactivate target
genes. In cancer, genetic alterations in tumor suppressor
genes and oncogenes also induce HIF-1a and HIF-2a
overexpression, and lead to the transactivation of target
genes. MAPK signaling downstream of ras has been
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shown to lead to the phosphorylation of HIF-1a and,
thereby, stimulate its transcriptional activity [11,14].
Both HIF-1a and HIF-2a induce the expression of tar-
get genes important for tumor angiogenesis, cell growth
and survival, and metastasis [7,15,16]. To date, regula-
tion of cancer glucose metabolism has been predomi-
nantly linked to HIF-1a rather than HIF-2a. HIF-1a
induces the expression of glucose transporters and gly-
colytic enzymes that promote glucose uptake and glyco-
lysis [17,18]. This has been well demonstrated under
hypoxic conditions; and more recently under normoxic
conditions [10,19,20]. HIF-1a was also recently shown
to induce the expression of pyruvate dehydrogenase
kinase 1 (PDK1) under hypoxic conditions [21,22].
PDK1 is a kinase that inhibits pyruvate dehydrogenase
(PDH), an enzyme that catalyzes the conversion of pyru-
vate to acetyl-CoA. This leads to suppression of pyru-
vate entry into the TCA cycle, with consequent
suppression of mitochondrial oxygen consumption.
Through these mechanisms, HIF-1a is thought to med-
iate aerobic glycolysis and contributes to carcinogenesis.
Furthermore, both HIF-1a and HIF-2a were shown to
regulate the exchange of COX4 (cytochrome c oxidase
4) subunits under hypoxic conditions; thereby increasing
mitochondrial respiration efficiency and decreasing ROS
production [23]. These findings implicate HIF-1a and
HIF-2a in balancing glycolysis and aerobic respiration
to maintain ATP production and prevent toxic ROS
generation [23].
To understand the individual and combined roles of
HIF-1a and HIF-2a in cancer metabolism and onco-
genic KRAS signaling, we used targeted homologous
recombination to disrupt the oncogenic KRAS, HIF-1a,
and HIF-2a gene loci in HCT116 colon cancer cells to
generate isogenic HCT116WT KRAS, HCT116HIF-1a-/-,
HCT116HIF-2a-/-, and HCT116HIF-1a-/-HIF-2a-/- cell lines.
These cell lines are then subjected to global gene
expression analyses. We characterized the metabolic
adaptation mediated by oncogenic KRAS and both HIF-
1a and HIF-2a.
Results
The metabolic transcriptomes regulated by oncogenic
KRAS and by both HIF-1a and HIF-2a show significant
overlap
HCT116 cell line with targeted disruption of the onco-
genic KRAS allele was generated by targeting exon 2 for
homologous recombination, as previously described [20].
This resulted in HCT116 cells with just the wild-type
allele (HCT116WT KRAS), as confirmed by genomic DNA
sequencing of these cell lines (Additional file 1, Fig. S1).
The HIF-1a gene locus was disrupted by targeting exons
3 and 4; and the HIF-2a gene locus was disrupted by tar-
geting exons 5 and 6 for homologous recombination, as
previously described [20]. Loss of HIF-1a, HIF-2a, and
both HIF-1a and HIF-2a proteins in the resultant
isogenic knockout cell lines (HCT116HIF-1a-/-,
HCT116HIF-2a-/-, and HCT116HIF-1a-/-HIF-2a-/-) were con-
firmed by Western blot analysis (Additional file 2, Fig. S2).
To systematically identify genes that are regulated by
HIF-1a, HIF-2a, both HIF-1a and HIF-2a, and onco-
genic KRAS we performed global gene expression ana-
lyses on HCT116, HCT116HIF-1a-/-, HCT116HIF-2a-/-,
HCT116HIF-1a-/-HIF-2a-/-, and HCT116WT KRAS cells.
Using a cut-off of > 2.0-fold difference in gene expres-
sion between HCT116 versus HCT116HIF-1a-/-HIF-2a-/-
cells, we identified genes regulated exclusively by HIF-
1a or HIF-2a, and by both HIF-1a and HIF-2a. The
expression of some of these genes was confirmed by
real-time RT-PCR (Figure 1). Consistent with the litera-
ture, some genes were exclusively HIF-1a targets,
including those involved in glycolysis (HK2, LDHA);
some genes were exclusively HIF-2a targets, i.e.
ANGPTL4 and MGLL; and some genes were HIF-1a
and HIF-2a co-regulated targets, i.e. VEGFA (Figure 1).
To determine whether HIF-1a and HIF-2a target genes
are also downstream targets of oncogenic KRAS, we
compared the gene sets regulated by HIF-1a, HIF-2a,
and by both HIF-1a and HIF-2a with the gene set regu-
lated by oncogenic KRAS (HCT116 versus HCT116WT
KRAS). We found that oncogenic KRAS regulates genes
that were induced by HIF-1a alone, HIF-2a alone, or by
both HIF-1a and HIF-2a (Figure 1).
To focus on the regulation of genes controlling nutri-
ents metabolism, we performed a heatmap analysis of
genes categorized by the “GO” term “metabolism” (Fig-
ure 2A). The gene terms and fold changes are shown in
Table 1. Using the color blue for negatively and red for
positively regulated genes and data analysis using Venn
diagrams, we made the following observations. First,
HIF-1a and HIF-2a regulate both overlapping and
unique metabolism genes (Figure 2A-B). To our sur-
prise, the absence of HIF-2a led to a greater change in
the number of affected metabolism genes than the
absence of HIF-1a (Figure 2B). The absence of both
HIF-1a and HIF-2a led to an increase in both the num-
ber and change in expression levels of affected genes
(Figure 2A-B). Second, the metabolic gene set regulated
by oncogenic KRAS showed significant overlap with
the metabolic gene set regulated by both HIF-1a and
HIF-2a (HCT116 versus HCT116WT KRAS in compari-
son to HCT116 versus HCT116HIF-1a-/-HIF-2a-/-) (Figure
2A-B). This similarity in the metabolic gene sets reflects
the similar extent of suppression of clonogenic survival
upon loss of oncogenic KRAS or both HIF-1a and
HIF-2a (Figure 2C).
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Absence of oncogenic KRAS or both HIF-1a and HIF-2a
reduced the expression of enzymes regulating essential
steps in mitochondrial phospholipids synthesis
Combing through the gene expression data for groups
of genes participating in the same metabolic pathway,
we identified three genes regulated by oncogenic KRAS
and by both HIF-1a and HIF-2a: ACSL5, PCK2, and
AGPAT7 (Table 1). These genes encode for enzymes
that catalyze rate-limiting steps in phospholipids bio-
synthesis (Figure 3A). PCK2, or phosphoenolpyruvate
carboxykinase 2, is a mitochondrial enzyme that cata-
lyzes the conversion of oxaloacetate to phosphoenolpyr-
uvate in the mitochondria, a rate-limiting step in
glyceroneogenesis. ACSL5, or acyl-CoA synthetase 5, is
a mitochondrial enzyme that catalyzes the formation of
acyl-CoA, which together with glycerol-3-phosphate
forms essential intermediates for phospholipids synth-
esis. ACSL5 has been shown to induce the synthesis of the
mitochondrial phospholipid, cardiolipin [24]. Based on
sequence homology to other members of the 1-acyl-sn-
glycerol-3-phosphate acyltransferase (AGPAT), AGPAT7
is thought to participate in the conversion of lysophospha-
tidic acid to phosphatidic acid in phospholipids biosynth-
esis. However, the specific function of AGPAT7 and its
subcellular localization have not been defined.
The expression of all three genes in HCT116 cells was
confirmed by real-time RT-PCR (Figure 3B). They are
induced by oncogenic KRAS and also required the pre-
sence of both HIF-1a and HIF-2a for maximal induc-
tion (Figure 3B). To further determine the relevance of
these genes to the pathogenesis of colorectal cancer, we
compared their expression in primary colorectal cancer
specimens and matched normal mucosa (Figure 3C). All
three genes were significantly induced in tumors com-
pared to normal mucosa (Figure 3C).
This data suggested an as yet unidentified role for
oncogenic KRAS, HIF-1a, and HIF-2a in mitochondrial
phospholipids synthesis. To determine how mitochon-
drial cardiolipin synthesis is regulated, we went on and
further characterize ACSL5. Similar to ACSL5 mRNA
level, the absence of either HIF-1a or HIF-2a led to
decrease in ACSL5 protein level; and the absence of
both HIF-1a and HIF-2a or oncogenic KRAS led to the
most significant reduction (Figure 3B and 3D).
We next asked whether HIF-1a and HIF-2a regulate
the ACSL5 promoter. Examination of the 5’-flanking
sequence of the ACSL5 gene, using TFSEARCH engine,
revealed a hypoxia response element (HRE; RCGTG,
where R is A or G) indicating a putative HIF-a binding
site (Figure 3E). To determine if HIF-1a and HIF-2a
transactivate the ACSL5 promoter, we measured ACSL5
promoter activity using dual-luciferase assays. An 1883
bp fragment derived from the 5’ untranslated region of
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Figure 1 Analyses of genes regulated by oncogenic KRAS, HIF-
1a, HIF-2a, and both HIF-1a and HIF-2a. Expression of target
genes in HCT116, HCT116HIF-1a-/-, HCT116HIF-2a-/-, HCT116HIF-1a-/-HIF-
2a-/-, and HCT116WT KRAS cell lines. HK2, hexokinase 2; LDHA, lactate
dehydrogenase A; MGLL, monoglyceride lipase; ANGPTL4,
angiopoietin-like protein 4; and VEGFA, vascular endothelial growth
factor A relative to b-actin were measured by real-time reverse
transcription-PCR (n = 5). Bars, stdev. p < 0.05 by Student’s t test
comparing knockout cells with parental HCT116 cells. c, clone.
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the ACSL5 gene, containing the HRE site, was linked to
a minimal promoter Firefly luciferase reporter construct
(pGL3pro) to generate the ACSL5-pGL3pro construct.
To determine the role of HIF-1a and HIF-2a binding,
we performed site-directed mutagenesis at the HRE site
to generate the construct ACSL5(-HRE)-pGL3pro.
These three constructs (pGL3pro, ACSL5-pGL3pro, and
ACSL5(-HRE)-pGL3pro) were separately co-transfected
with CMV-Renilla luciferase into HCT116, HCT116HIF-
1a-/-, HCT116HIF-2a-/-, HCT116HIF-1a-/-HIF-2a-/-, and
HCT116WT KRAS cells (Figure 3E). In HCT116 cells,
transfection with ACSL5-pGL3pro led to ~2.3-fold
induction in Firefly luciferase activity in comparison to
transfection with either pGL3pro or ACSL5(-HRE)-
pGL3pro (Figure 3E). The absence of HIF-1a, HIF-2a,
both HIF-1a and HIF-2a, or oncogenic KRAS led to an
almost complete suppression of Firefly luciferase activity
(Figure 3E). Altogether, these data suggest that HIF-1a
and HIF-2a directly transactivate the ACSL5 promoter
at the HRE site.
Absence of oncogenic KRAS or both HIF-1a and HIF-2a
led to decreased cardiolipin level and inefficient
mitochondrial respiration
We have identified three enzymes important for early
steps in phospholipids synthesis (ACSL5, PCK2, and
AGPAT7) whose coordinated expressions are induced
by oncogenic KRAS, and by HIF-1a and HIF-2a.
ACSL5 has been shown to induce the synthesis of the
mitochondrial phospholipid, cardiolipin [24].
Cardiolipin is an important component of the inner
mitochondrial membrane, where it constitutes about
20% of the total lipid. Cardiolipin serves as an insulator
by interacting with electron transport chain proteins to
optimize respiration. Mitochondria deficient in cardio-
lipin malfunction, which result in decreased ATP
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production and increased ROS generation [25,26]. We
next asked whether total cellular phosphatidyl choline
(PC) and cardiolipin (CL) levels are affected by
the expression of oncogenic KRAS, and HIF-1a and
HIF-2a. We compared the following sets of cell
lines: HCT116, HCT116HIF-1a-/-, HCT116HIF-2a-/-,
HCT116HIF-1a-/-HIF-2a-/-, and HCT116WT KRAS cells.
Phospholipids species were measured in collaboration
with Lipomics Technology Inc. We found that CL level
was significantly decreased in the absence of HIF-1a,
HIF-2a, or oncogenic KRAS; and was most decreased in
the absence of both HIF-1a and HIF-2a (Figure 4). PC
level was also decreased but to a lesser extent.
To determine effects on mitochondrial respiratory
function, we first measured cellular oxygen (O2) con-
sumption; as mitochondrial respiration is the main
source for cellular O2 consumption. We found that loss
of both HIF-1a and HIF-2a or oncogenic KRAS signifi-
cantly decreased cellular O2 consumption (Figure 5A).
Decrease in mitochondrial respiration can result from
either decreased flux through the TCA cycle or less effi-
cient mitochondrial respiration. We began to address
these two possibilities by measuring TCA cycle activity
and mitochondrial respiration efficiency.
To determine TCA cycle activity, we measured the
activity of one of the TCA cycle enzymes, succinate
dehydrogenase, which can be measured by the reduction
of methylthiazoletetrazolium (MTT) dye [27]. We found
that loss of both HIF-1a and HIF-2a or oncogenic
KRAS increased MTT reduction (Figure 5B). Our result
suggests that the decrease in O2 consumption upon loss
of both HIF-1a and HIF-2a or oncogenic KRAS is not
due to decreased flux through the TCA cycle; in fact,
there is increased flux through the TCA cycle. Thus, the
decrease in mitochondrial respiration might be second-
ary to decreased mitochondrial respiration efficiency.
Mitochondrial respiration efficiency is dependent on
the efficiency of the electron transport chain. The mito-
chondrial respiratory chain consists of four complexes
(I-IV). Electrons are transferred through a series of
acceptor cytochromes in complexes I-III. At complex
IV, O2 serves as the final electron acceptor, and is
reduced to water. At complexes I, III, and IV, protons
are pumped outward across the inner mitochondrial
membrane, thus creating an electrochemical gradient
with negative charges inside the mitochondrial matrix.
The electrochemical gradient generated is then effi-
ciently coupled to ATP production by the inward flow
of protons at the F1F0ATP synthase complex. Inefficient
electron transfers through the electron transport chain
may lead to early transfer of electrons to O2 at com-
plexes I and III and form ROS. Dysfunction at complex
IV may lead to inability to couple the electrochemical
gradient with ATP production. Thus, measurements of
Table 1 Fold change in expression of metabolism genes
HCT116 versus
Gene
symbol
HCT116HIF-1a-/- HCT116HIF-2a-/- HCT116HIF-1a-/-HIF-2a-/-
ACAT2 1.435 1.346 3.037
GSTP1 1.416 1.257 2.552
G6PD 1.068 1.144 5.369
METTL7B 1.723 0.758 2.947
GSTM4 1.519 0.667 2.643
NAT1 1.799 0.857 2.513
SULF2 1.047 0.584 3.444
UGT8 0.833 0.543 2.312
PCAF 1.131 0.617 3.6
ABP1 1.17 1.524 7.443
ALPP 1.193 2.608 5.763
METTL7A 0.831 1.017 2.359
MDH1B 0.915 0.943 2.237
MAN1C1 1.333 0.775 2.076
CRYZL1 1.214 0.756 2.252
LSS 1.103 0.898 2.052
HIBCH 1.021 0.757 2.094
SRR 0.988 0.598 2.04
ZADH2 0.665 0.725 2.381
TP53I3 1.116 1.06 3.215
ALPPL2 0.887 1.537 3.467
ALDH7A1 0.985 1.215 2.211
ACAA2 1.1 1.466 2.539
DHRS2 5.301 0.304 2.496
DHRS3 0.492 0.515 0.306
DPYD 0.445 0.268 0.251
ASNS 0.646 0.816 0.126
BCKDHA 0.544 0.944 0.315
PCK2 0.661 0.798 0.214
TMEM68 0.849 1.18 0.38
ALDOC 0.62 1.178 0.301
PSAT1 0.787 0.98 0.257
ATP9A 0.71 0.445 0.257
RDHE2 0.841 0.405 0.443
MOCOS 0.797 0.419 0.361
PHGDH 0.391 0.738 0.321
ACSM3 0.448 0.512 0.488
ACSS2 0.603 0.717 0.371
MTHFD1L 0.574 0.99 0.378
GAA 0.726 0.474 0.464
GFPT1 0.793 0.644 0.499
UAP1 0.99 0.886 0.406
AGPAT7 1.028 0.757 0.428
PLD3 0.96 0.651 0.453
PLA2G4C 1.301 0.608 0.37
LIAS 1.213 0.897 0.493
PYCR1 1.005 0.76 0.444
MECR 0.858 0.766 0.494
ACSL5 0.228 0.334 0.055
MMP1 0.395 0.07 0.059
Note: expression values are normalized to those in HCT116 cells.
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Figure 3 Analyses of target genes regulating phospholipids synthesis. A, overview of mitochondrial respiration and the contributory role of
mitochondrial phospholipids synthesis. B, expression of genes regulating phospholipids synthesis in HCT116, HCT116HIF-1a-/-, HCT116HIF-2a-/-,
HCT116HIF-1a-/-HIF-2a-/-, and HCT116WT KRAS cell lines. c, clone. ACSL5, acyl-CoA synthetase 5; AGPAT7, 1-acyl-sn-glycerol-3-phosphate acyltransferase
7; and PCK2, phosphoenolpyruvate carboxykinase 2 relative to b-actin were measured by real-time reverse transcription-PCR (n = 5). Bars, stdev. p
< 0.05 by Student’s t test comparing knockout cells with parental HCT116 cells. C, Expression of ACSL5, AGPAT7, and PCK2 in primary colon
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clone. E, ACSL5 promoter activity in HCT116, HCT116HIF-1a-/-, HCT116HIF-2a-/-, and HCT116HIF-1a-/-HIF-2a-/- cells (n = 5). Diamond represents HRE site.
The pGL3pro construct is a minimal promoter Firefly luciferase reporter. The ACSL5-pGL3pro construct contains an 1883 bp fragment of the 5’
untranslated region of the ACSL5 gene with the HRE site. This construct is subjected to site-directed mutagenesis at the HRE site to generate the
ACSL5(-HRE)-pGL3pro. Bars, stdev. p < 0.05 by Student’s t test comparing transfection with pGL3pro construct versus ACSL5-pGL3pro or ACSL5
(-HRE)-pGL3pro constructs.
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cellular ATP level and ROS production would reflect the
efficiency of mitochondrial respiration. We found that
loss of both HIF-1a and HIF-2a or oncogenic KRAS in
HCT116 cells led to decreased ATP level, and increased
cellular and mitochondrial ROS levels (Figure 5C and
5D). Quantitation of the flow cytometry tracings shows
2.1-fold and 2.1-fold increases in total cellular ROS; and
1.9-fold and 1.8-fold increases in mitochondrial ROS
upon loss of both HIF-1a and HIF-2a, and oncogenic
KRAS, respectively. Altogether, these data show that the
presence of oncogenic KRAS and both HIF-1a and HIF-
2a in cancer cells lead to increased cardiolipin level and
enhanced mitochondrial respiration efficiency.
Induction of ACSL5 is directly responsible for maintaining
cardiolipin level and efficient mitochondrial respiration in
cancer
We next asked whether the induction of ACSL5 directly
contributes to the increase in cellular phospholipids
levels and efficient mitochondrial respiration. We
suppressed ACSL5 expression in HCT116 and LOVO
human colon cancer cells using lentiviral shRNA (Addi-
tional file 3, Fig. S3). In comparison to transduction
with lentivirus carrying control scramble shRNA, trans-
duction by lentivirus carrying ACSL5 shRNA led to
decreased PC and CL levels (Figure 4). Compared to
transduction with lentivirus carrying control scramble
shRNA, transduction by lentivirus carrying ACSL5
shRNA also led to decreased cellular O2 consumption,
decreased ATP production, and increased ROS produc-
tion (Figure 6A-C). Quantitation of the flow cytometry
tracings shows 1.5-fold and 1.5-fold increases in total
cellular ROS and mitochondrial ROS upon suppression
of ACSL5 expression.
Discussion
Cellular transformation relies on molecular signals that
promote cell proliferation, obstruct cell death, inhibit
cellular differentiation, and induce angiogenesis. Under-
lying these cellular processes, transformed cells also
Figure 4 Quantitation of total cellular (A) phosphatidyl choline (PC) and (B) cardiolipin (CL) levels in HCT116, HCT116HIF-1a-/-HIF-2a-/-,
HCT116WT KRAS cells, HCT116 cells transduced with control scramble shRNA, and HCT116 cells transduced with ACSL5 shRNA (n = 3).
Bars, stdev. p < 0.05 by Student’s t test comparing knockout cells or shRNA transduced cells with parental HCT116 cells. Four lentiviral constructs
carrying ACSL5 shRNA were tested for effectiveness in suppressing ACSL5 expression in comparison to the lentiviral construct carrying control
scramble shRNA (Additional file 3, Fig. S3). Clone H45551 was chosen for subsequent experiments as it was the most effective (Additional file 3,
Fig. S3).
A MTT reduction
0
0.5
1
1.5
2
1 2 3
MTT reduction
0
1.0
2.0
R
el
at
iv
e 
fo
ld
 c
ha
ng
e
B E
ATP
0
0.5
1
1.5
1 2 3
.
1.0
.
0Re
la
tiv
e 
fo
ld
 c
ha
ng
e
C
ATP
D
CM-H2DCFDA MitoSOX
Log fluorescence
E
ve
nt
s
O2 consumption
0
0.5
1
1.5
1 2 3
0
0.5
1.0
1.5
R
el
at
iv
e 
fo
ld
 c
ha
ng
e
O2 consumption
Figure 5 Effects of genetic inactivation of oncogenic KRAS or both HIF-1a and HIF-2a on mitochondrial metabolism. A, change in
cellular O2 consumption; B, change in MTT reduction; and C, change in intracellular ATP level in HCT116
HIF-1a-/-HIF-2a-/- and HCT116WT KRAS
relative to HCT116 cells (n = 5). Bars, stdev. p < 0.05 by Student’s t test comparing knockout cells with parental HCT116 cells. D, cellular and
mitochondrial ROS levels in HCT116, HCT116HIF-1a-/-HIF-2a-/-, and HCT116WT KRAS cells, as measured by the fluorescent dyes CM-H2DCFDA and
MitoSOX.
Chun et al. Molecular Cancer 2010, 9:293
http://www.molecular-cancer.com/content/9/1/293
Page 7 of 11
undergo significant metabolic adaptation [28-30]. In fact,
many mutations important for the cancer phenotype
control glucose metabolism.
We present a novel mechanism whereby cancer cells
with oncogenic KRAS mutation, and expressing both
HIF-1a and HIF-2a, can maximize ATP production and
minimize ROS generation. The proposed mechanism is
through the induction of enzymes important for mito-
chondrial cardiolipin synthesis. Cardiolipin is a mito-
chondria-specific phospholipid that intimately associates
with numerous mitochondrial proteins, including
complexes I-IV and F1F0ATP synthase. In this process,
cardiolipin optimizes efficient electron transfer and max-
imizes ATP production, with minimal ROS generation.
The role of mitochondrial respiration in cancer has
not been clearly elucidated. Two lines of evidence sug-
gest that mitochondrial respiration might be important
for cancer cells. First, cancer cells are metabolically
active, which suggest that they may require efficient
mitochondria. While some data have associated
decreased tumorigenicity with metabolic conversion to
mitochondrial respiration; other data have shown that
the induction of mitochondrial biogenesis and respira-
tion are associated with transformation [5,31]. For
example, overexpression of the MYC oncogene has
been shown to increase mitochondrial biogenesis and
respiration [31]. Second, transformation by HRAS in
human fibroblasts and bronchial epithelial cells not
only increases glycolysis, but also increases mitochon-
drial respiration [5,32,33]. Our findings are consis-
tent with these observations, suggesting that the
induction of mitochondrial respiration contributes to
carcinogenesis.
Our findings also have important clinical implications.
It has recently been shown that therapies targeting the
epidermal growth factor receptor (EGFR) provided clini-
cal benefit in patients with head and neck, pancreatic,
colorectal, and lung cancers. The mechanism of efficacy
is through the inhibition of MAPK and PI3K/AKT signal-
ing pathways, which are important for cell growth and
cell survival, respectively. However, cancers with onco-
genic KRAS mutations are primarily resistant, due to per-
sistent signaling through these pathways [34,35]. Our
data suggest that agents inhibiting both HIF-1a and HIF-
2a, or their target genes, may likely be effective in treat-
ing cancers with oncogenic KRAS mutations.
To date, high-throughput small-compound screens have
identified several classes of anticancer agents that disrupt
HIF-1a function; including inhibition of its transcriptional
activity, synthesis, or protein stability [7,36]. Due to the
partial structural and functional similarities between HIF-
1a and HIF-2a, some of the already identified HIF-1a
inhibitors also inhibit HIF-2a. Our data suggest that it
may be advantageous to further develop compounds that
are effective at inhibiting both HIF-1a and HIF-2a for
cancer treatment. As such, these isogenic HIF1a and HIF-
2a knockout cell lines would provide invaluable tools for
primary and secondary screens to systematically identify
dual HIF-1a and HIF-2a inhibitors.
Methods
Cell lines
All cancer cell lines were acquired from the American
Type Culture Collection (Manassas, VA). HCT116 and
LOVO are human colon cancer cell lines. Isogenic cell
lines with somatic disruption of oncogenic KRAS, HIF-
1a, and HIF-2a genes were derived from HCT116
(HCT116WT KRAS, HCT116HIF-1a-/-, HCT116HIF-2a-/-,
HCT116HIF-1a-/-HIF-2a-/-) cells as previously described
[30]. Cells were grown in McCoy5A media, supplemen-
ted with 10% FBS and 1% penicillin/streptomycin (Invi-
trogen, Carlsbad, CA).
Clonogenic survival assay
Cells were trypsinized, counted, and then seeded at low
density (5000 cells per well) on six-well tissue culture
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plates and allowed to grow undisturbed at 37°C, in 5%
CO2 for 10 days and then stained with crystal violet.
Gene expression profiling
HCT116, HCT116HIF-1a-/-, HCT116HIF-2a-/-, HCT116HIF-
1a-/-HIF-2a-/-, and HCT116wt K-RAS cells were seeded at
low density 5000 cells per well on 6-well tissue culture
plates and allowed to grow undisturbed at 37°C, in 5%
CO2 for 10 days. Cells were then harvested and total
RNA extracted. Gene expression analyses on the sam-
ples were performed at the University of Michigan
Comprehensive Cancer Center Affymetrix Core Facility.
Commercial high-density oligonucleotide arrays were
used (GeneChip Human Genome U133A; Affymetrix,
Inc., San Clara, CA), following protocols and methods
developed by the supplier.
Real-time reverse transcription (RT)-PCR analysis
Total RNA from cell lines or xenografts were extracted,
treated with DNAse I, and reverse transcribed as pre-
viously described [37]. Real-time PCR reactions were
performed in triplicate on RT-derived cDNA, and rela-
tive values calculated as previously described [37]. Stu-
dent’s paired t test was used to determine statistical
significance between groups.
Western blot analysis
Whole-cell protein extracts were prepared from cells,
separated by electrophoresis, transferred to nitrocellu-
lose membranes, and probed with antibodies as
described previously [20]. Antibodies were obtained
from BD Transduction Laboratories (San Jose, CA;
mouse anti-human HIF-1a), Sigma (St. Louis, MO; a-
tubulin), Novus Biologicals (Littleton, CO; rabbit anti-
human HIF-2a and mouse anti-human ACSL5), Pierce
(Rockford, IL; peroxidase-conjugated anti-rabbit anti-
body), and Jackson Immunoresearch Laboratories (West
Grove, PA; peroxidase-conjugated anti-mouse antibody).
Antibody dilutions were as recommended by the
manufacturer.
Site-directed mutagenesis and dual-luciferase assay
An 1883 bp fragment from the 5’ untranslated region of
the ACSL5 gene containing the hypoxia response ele-
ment (HRE) indicating a putative HIF-a binding site
was PCR amplified and subcloned into the minimal pro-
moter Firefly luciferase reporter construct, pGL3pro
(Promega, Madison, WI). The HRE site is denoted as a
diamond in Figure 2E and is located at +2066 from
transcriptional initiation. The resulting ACSL5-pGL3pro
contruct was subjected to site-directed mutagenesis at
the HRE site to generate the ACSL5(-HRE)-pGL3pro
construct. For site-directed mutagenesis, the HRE site at
position -18723 from translation start was mutated from
CACGT to GGGGT using the Quickchange site-direc-
ted mutagenesis kit (Stratagene, La Jolla, CA). These
three constructs (pGL3pro, ACSL5-pGL3pro, and
ACSL5(-HRE)-pGL3pro) were separately co-transfected
with CMV-Renilla luciferase reporter construct into
cells using Lipofectamine as previously described [37].
Luciferase activity was measured using the Dual-Lucifer-
ase Reporter Assay System (Promega, Madison, WI).
These studies were performed on cells grown on 6-well
plates at 50-70% confluence. Student’s paired t test was
used to determine statistical significance between
groups.
Phosphatidyl choline and cardiolipin measurement
Phospholipids were measured by the methods of Folch
et al., in collaboration with Lipomics Technologies, Inc.
(West Sacramento, CA) [38]. Lipids from cells were
extracted in the presence of internal standards using
chloroform:methanol (2:1 v/v). Individual lipid classes
within each extract were separated by liquid chromato-
graphy. Each lipid class was trans-esterified in 1% sulfu-
ric acid in methanol in a sealed vial under a nitrogen
atmosphere at 100°C for 45 min. The resulting fatty acid
methyl esters were extracted from the mixture with hex-
ane containing 0.05% butylated hydroxytoluene and pre-
pared for gas chromatography by sealing the hexane
extracts under nitrogen. Fatty acid methyl esters were
separated and quantified by capillary gas chromatogra-
phy equipped with a 30 m DB-88MS capillary column
and a flame-ionization detector. Student’s paired t test
was used to determine statistical significance between
groups.
Cellular oxygen (O2) consumption assay
Cells were transferred to a 96-well O2 Biosensor plate
(BD Biosciences, San Jose, CA), at a density of 250,000
cells per well. After two hours, fluorescence was mea-
sured at excitation/emission of 485 nm/630 nm. Stu-
dent’s paired t test was used to determine statistical
significance between groups.
Methylthiazoletetrazolium (MTT) reduction
Succinate dehydrogenase activity was measured by the
reduction of methylthiazoletetrazolium (MTT) dye,
using the CellTiter 96 Assay (Promega, Madison, WI).
Student’s paired t test was used to determine statistical
significance between groups.
ATP measurement
Cells were harvested and lysed by repeated freeze-thaw
cycles. Intracellular ATP concentrations were measured
using the ATP assay kit (Biomedical Research Service
Center at State University of New York, Buffalo, NY). In
the presence of ATP, the enzyme luciferase catalyzes the
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oxidation of luciferin with concomitant emission of yel-
low green light. Measurements were made on a lumin-
ometer and compared with a standard curve of ATP
concentrations. Student’s paired t test was used to deter-
mine statistical significance between groups.
ROS measurement
For measurement of cellular ROS, cells were incubated
with 5 μM CM-H2DCFDA (Invitrogen, Carlsbad, CA)
for 1 hour at 37°C, then analyzed by flow cytometry
with excitation and emission wavelengths, 488/525 nm.
For measurement of mitochondrial ROS, cells were
incubated with 5 μM MitoSOX Red (Invitrogen, Carls-
bad, CA) for 15 minutes at 37°C, then analyzed by flow
cytometry with excitation and emission wavelengths,
510/580 nm.
Gene knockdown
The ACSL5 gene was suppressed using lentiviral shRNA
clones from Open Biosystems repository (Huntsville,
AL), which is made available by the RNAi Consortium.
The constructs were tested to identify ones that can
achieve the most efficient knockdown. Negative control
was scramble shRNA cloned into the same vector
(pLKO.1) (Addgene, Cambridge, MA). For generation of
viral stocks, 293T cells were seeded on 100-mm dishes
1 day prior to transfection. Lentiviral constructs (3 μg)
together with the lentiviral helper pHR’8.2dR and
pCMV-VSV-G vectors (3 μg and 0.3 μg, respectively)
were cotransfected into 293T cells by the FuGENE 6
Transfection Reagent according to manufacturer’s proto-
col (Roche, Indianapolis, IN). The lentiviral supernatants
were collected 48 hours after transfection and stored in
aliquots at -80°C. Cancer cells grown in 6-well plate at
subconfluence were transduced with 2 ml shRNA lenti-
viral supernatant in the presence of 8 μg/ml polybrene.
The supernatant was replaced with growth medium
after 1 day, and cells were selected with antibiotics on
day 2 post-transduction.
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Additional file 1: Confirmation of the disruption of the oncogenic
KRAS allele in HCT116WT KRAS cells. Sequencing of genomic DNA at
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oncogenic mutant and wild-type alleles at codon 13, whereas HCT116WT
KRAS cells have only wild-type alleles.
Additional file 2: Confirmation of the disruption of HIF-1a and/or
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antibodies to HIF-1a and HIF-2a were done, with antibody to a-tubulin
as loading control. c, clone.
Additional file 3: Testing of ACSL5 knockdown by four lentiviral
shRNA clones in comparison to lentiviral clone carrying scramble
shRNA. ACSL5 mRNA level relative to b-actin was measured by real-time
reverse transcription-PCR (n = 5). Bars, stdev. Clone H45551 was the most
effective in suppressing ACSL5 expression.
Acknowledgements
This study was funded by the National Comprehensive Cancer Network
(NCCN) from general research support provided by Pfizer, Inc, NIH Grant
K22CA111897, and NIH Grant R21CA115809. We thank Ann Marie Deslauriers
and David Adams for assistance with flow cytometry (University of Michigan
Comprehensive Cancer Center Flow Cytometry Core Facility); Karen Kreutzer
and Pamela Varga for administrative assistance.
Author details
1University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA.
2The University of Michigan Comprehensive Cancer Center Affymetrix and
cDNA Microarray Core Facility, Ann Arbor, MI, USA. 3The University of Puerto
Rico Cancer Center, San Juan, PR, USA. 4Division of Gastroenterology,
Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
5Division of Hematology/Oncology, Department of Internal Medicine,
University of Florida Shands Cancer Center, University of Florida, Gainesville,
FL, USA.
Authors’ contributions
SC performed the cellular assays, molecular studies, and Western blots. CJ
and JW carried out the microarray gene expression analysis and
bioinformatics. MC provided patients’ tumor samples with matched normal
tissue. DD participated in the study design and performed the stastistical
analysis. LD conceived the study, participated in study design, coordinated
the experiments, and drafted the manuscript. All authors have read and
approved the final manuscript.
Received: 17 May 2010 Accepted: 13 November 2010
Published: 13 November 2010
References
1. Bos JL: ras oncogenes in human cancer: a review. Cancer Res 1989,
49(17):4682-9.
2. Friday BB, Adjei AA: K-ras as a target for cancer therapy. Biochim Biophys
Acta 2005, 1756(2):127-44.
3. Weinberg RA: ras Oncogenes and the molecular mechanisms of
carcinogenesis. Blood 1984, 64(6):1143-5.
4. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000, 100(1):57-70.
5. Ramanathan A, Wang C, Schreiber SL: Perturbational profiling of a cell-line
model of tumorigenesis by using metabolic measurements. Proc Natl
Acad Sci USA 2005, 102(17):5992-7.
6. Harris AL: Hypoxia–a key regulatory factor in tumour growth. Nat Rev
Cancer 2002, 2(1):38-47.
7. Semenza GL: Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003,
3(10):721-32.
8. Ema M, et al: A novel bHLH-PAS factor with close sequence similarity to
hypoxia-inducible factor 1alpha regulates the VEGF expression and is
potentially involved in lung and vascular development. Proc Natl Acad
Sci USA 1997, 94(9):4273-8.
9. Flamme I, et al: HRF, a putative basic helix-loop-helix-PAS-domain
transcription factor is closely related to hypoxia-inducible factor-1 alpha
and developmentally expressed in blood vessels. Mech Dev 1997,
63(1):51-60.
10. Karni R, et al: Activated pp60c-Src leads to elevated hypoxia-inducible
factor (HIF)-1alpha expression under normoxia. J Biol Chem 2002,
277(45):42919-25.
11. Richard DE, et al: p42/p44 mitogen-activated protein kinases
phosphorylate hypoxia-inducible factor 1alpha (HIF-1alpha) and enhance
the transcriptional activity of HIF-1. J Biol Chem 1999, 274(46):32631-7.
12. Kamura T, et al: Activation of HIF1alpha ubiquitination by a reconstituted
von Hippel-Lindau (VHL) tumor suppressor complex. Proc Natl Acad Sci
USA 2000, 97(19):10430-5.
Chun et al. Molecular Cancer 2010, 9:293
http://www.molecular-cancer.com/content/9/1/293
Page 10 of 11
13. Ohh M, et al: Ubiquitination of hypoxia-inducible factor requires direct
binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell
Biol 2000, 2(7):423-7.
14. Mylonis I, et al: Identification of MAPK phosphorylation sites and their
role in the localization and activity of hypoxia-inducible factor-1alpha. J
Biol Chem 2006, 281(44):33095-106.
15. Chan DA, Giaccia AJ: Hypoxia, gene expression, and metastasis. Cancer
Metastasis Rev 2007, 26(2):333-9.
16. Sowter HM, et al: Predominant role of hypoxia-inducible transcription
factor (Hif)-1alpha versus Hif-2alpha in regulation of the transcriptional
response to hypoxia. Cancer Res 2003, 63(19):6130-4.
17. Brahimi-Horn MC, Chiche J, Pouyssegur J: Hypoxia and cancer. J Mol Med
2007, 85(12):1301-7.
18. Semenza GL: HIF-1 mediates the Warburg effect in clear cell renal
carcinoma. J Bioenerg Biomembr 2007, 39(3):231-4.
19. Agrawal A, et al: Normoxic stabilization of HIF-1alpha drives glycolytic
metabolism and regulates aggrecan gene expression in nucleus
pulposus cells of the rat intervertebral disk. Am J Physiol Cell Physiol 2007,
293(2):C621-31.
20. Dang DT, et al: Hypoxia-inducible factor-1alpha promotes nonhypoxia-
mediated proliferation in colon cancer cells and xenografts. Cancer Res
2006, 66(3):1684-936.
21. Papandreou I, et al: HIF-1 mediates adaptation to hypoxia by actively
downregulating mitochondrial oxygen consumption. Cell Metab 2006,
3(3):187-97.
22. Kim JW, et al: HIF-1-mediated expression of pyruvate dehydrogenase
kinase: a metabolic switch required for cellular adaptation to hypoxia.
Cell Metab 2006, 3(3):177-85.
23. Fukuda R, et al: HIF-1 regulates cytochrome oxidase subunits to optimize
efficiency of respiration in hypoxic cells. Cell 2007, 129(1):111-22.
24. Mashima T, et al: p53-defective tumors with a functional apoptosome-
mediated pathway: a new therapeutic target. J Natl Cancer Inst 2005,
97(10):765-77.
25. Vreken P, et al: Defective remodeling of cardiolipin and
phosphatidylglycerol in Barth syndrome. Biochem Biophys Res Commun
2000, 279(2):378-82.
26. Gu Z, et al: Aberrant cardiolipin metabolism in the yeast taz1 mutant: a
model for Barth syndrome. Mol Microbiol 2004, 51(1):149-58.
27. Cooke D, O’Kennedy R: Comparison of the tetrazolium salt assay for
succinate dehydrogenase with the cytosensor microphysiometer in the
assessment of compound toxicities. Anal Biochem 1999, 274(2):188-94.
28. Warburg O: On the origin of cancer cells. Science 1956, 123(3191):309-14.
29. Bui T, Thompson CB: Cancer’s sweet tooth. Cancer Cell 2006, 9(6):419-20.
30. Gillies RJ, Gatenby RA: Adaptive landscapes and emergent phenotypes:
why do cancers have high glycolysis? J Bioenerg Biomembr 2007,
39(3):251-7.
31. Li F, et al: Myc stimulates nuclearly encoded mitochondrial genes and
mitochondrial biogenesis. Mol Cell Biol 2005, 25(14):6225-34.
32. Telang S, et al: The oncoprotein H-RasV12 increases mitochondrial
metabolism. Mol Cancer 2007, 6:77.
33. de Groof AJ, et al: Increased OXPHOS activity precedes rise in glycolytic
rate in H-RasV12/E1A transformed fibroblasts that develop a Warburg
phenotype. Mol Cancer 2009, 8:54.
34. Baselga J, Rosen N: Determinants of RASistance to anti-epidermal growth
factor receptor agents. J Clin Oncol 2008, 26(10):1582-4.
35. Khambata-Ford S, et al: Expression of epiregulin and amphiregulin and K-
ras mutation status predict disease control in metastatic colorectal
cancer patients treated with cetuximab. J Clin Oncol 2007, 25(22):3230-7.
36. Giaccia A, Siim BG, Johnson RS: HIF-1 as a target for drug development.
Nat Rev Drug Discov 2003, 2(10):803-11.
37. Chun SY, et al: CDX2 promotes anchorage-independent growth by
transcriptional repression of IGFBP-3. Oncogene 2007, 26(32):4725-9.
38. Folch J, Lees M, Stanley Sloane GH: A simple method for the isolation and
purification of total lipides from animal tissues. J Biol Chem 1957,
226(1):497-509.
doi:10.1186/1476-4598-9-293
Cite this article as: Chun et al.: Oncogenic KRAS modulates
mitochondrial metabolism in human colon cancer cells by inducing
HIF-1a and HIF-2a target genes. Molecular Cancer 2010 9:293.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Chun et al. Molecular Cancer 2010, 9:293
http://www.molecular-cancer.com/content/9/1/293
Page 11 of 11
